So far, 20 independent investigations from different continents like North America (USA), Europe (Finland, Germany, Netherlands, France), Africa (South Africa), and Asia (China, Japan, and Korea) have identified MED12 somatic mutations in almost 1,616 uterine leiomyomas (out of 2,417 tumors tested; 66.85%). This evidence concerns the gene MED12 and Uterine leiomyoma.